• The Linsay et al. study demonstrated a significant efficacy of Gelclair^® in reducing pain scores in 33 head and neck cancer patients with oral mucositis receiving radiotherapy. 
• After Gelclair^® treatment, pain score was reduced by 57% after a maximum of 4 days of treatment, providing pain relief in 85% of patients.  

• Gelclair^® was well tolerated and effective in reducing pain associated with oral mucositis.

Reference:
Lindsay G et al.Australian Nursing Journal 2009; 16(9):30-3.